Lunai Bioworks receives additional Nasdaq delisting notice for market value non-compliance

summarizeSummary

Lunai Bioworks received an additional Nasdaq delisting notice for failing to meet the $35 million market value requirement, adding to its ongoing compliance challenges.

check_boxKey Events

• Additional Delisting Notice Received

  Lunai Bioworks received a formal notification from Nasdaq on April 28, 2026, regarding continued non-compliance with the $35 million Market Value of Listed Securities (MVLS) requirement, which may serve as an additional basis for delisting.

• Compounding Compliance Challenges

  This new MVLS deficiency adds to existing non-compliance issues with Nasdaq's bid price and stockholders' equity rules, for which the company was previously granted an exception until May 1, 2026 (Equity Rule) and June 1, 2026 (Bid Price Rule).

• Recent Efforts to Regain Compliance

  The company recently completed a $20 million merger to address the Equity Rule and received shareholder approval for a reverse stock split on May 8, 2026, to tackle the Bid Price Rule. However, these efforts are now overshadowed by the new MVLS deficiency.

• Extension Requested for Bid Price Rule

  Due to a short delay in the special meeting of stockholders, the company has requested an extension from the Nasdaq Hearings Panel to evidence compliance with the Bid Price Rule.

auto_awesomeAnalysis

Lunai Bioworks faces an additional delisting threat from Nasdaq due to its failure to meet the $35 million market value of listed securities requirement. This new deficiency compounds existing non-compliance issues related to bid price and stockholders' equity, despite recent efforts like a merger and approved reverse stock split. The company's ability to maintain its Nasdaq listing is increasingly precarious.